HK1201209A1 - Therapeutic agent for diabetes - Google Patents

Therapeutic agent for diabetes Download PDF

Info

Publication number
HK1201209A1
HK1201209A1 HK15101890.2A HK15101890A HK1201209A1 HK 1201209 A1 HK1201209 A1 HK 1201209A1 HK 15101890 A HK15101890 A HK 15101890A HK 1201209 A1 HK1201209 A1 HK 1201209A1
Authority
HK
Hong Kong
Prior art keywords
group
therapeutic
diabetes
prophylactic agent
acid
Prior art date
Application number
HK15101890.2A
Other languages
English (en)
Chinese (zh)
Inventor
久留郎
久留一郎
辻本俊亮
白倉尚
白仓尚
平光伸也
Original Assignee
帝人制药株式会社
国立大学法人鸟取大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 帝人制药株式会社, 国立大学法人鸟取大学 filed Critical 帝人制药株式会社
Publication of HK1201209A1 publication Critical patent/HK1201209A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15101890.2A 2012-01-27 2013-01-25 Therapeutic agent for diabetes HK1201209A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012015351 2012-01-27
JP2012-015351 2012-01-27
PCT/JP2013/051627 WO2013111870A1 (ja) 2012-01-27 2013-01-25 糖尿病の治療薬

Publications (1)

Publication Number Publication Date
HK1201209A1 true HK1201209A1 (en) 2015-08-28

Family

ID=48873581

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101890.2A HK1201209A1 (en) 2012-01-27 2013-01-25 Therapeutic agent for diabetes

Country Status (15)

Country Link
US (1) US20150005506A1 (enExample)
EP (1) EP2808018B1 (enExample)
JP (1) JP5924699B2 (enExample)
KR (1) KR20140134266A (enExample)
CN (1) CN104066430A (enExample)
AR (1) AR089812A1 (enExample)
AU (1) AU2013212865A1 (enExample)
BR (1) BR112014017902A2 (enExample)
CA (1) CA2862602A1 (enExample)
HK (1) HK1201209A1 (enExample)
IN (1) IN2014DN05972A (enExample)
MX (1) MX2014008484A (enExample)
RU (1) RU2014134845A (enExample)
TW (1) TW201334779A (enExample)
WO (1) WO2013111870A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628671B (zh) * 2015-02-10 2016-04-13 佛山市赛维斯医药科技有限公司 含苯基脒结构的硝基苯噻唑羧酸酰胺类化合物及用途
CN104610190B (zh) * 2015-02-10 2016-08-17 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途
CN104610188B (zh) * 2015-02-10 2016-07-27 佛山市赛维斯医药科技有限公司 含苯基脒结构的腈基苯噻唑羧酸酰胺类化合物、其制备及用途
CN104628672A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含苯基脒结构的烷氧苯基噻唑羧酸酰胺类化合物及用途
CN104628673A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构的腈基苯噻唑羧酸酰胺类化合物及用途
KR102473677B1 (ko) * 2015-08-17 2022-12-02 삼성디스플레이 주식회사 액정 표시 장치
JP6732004B2 (ja) 2016-02-19 2020-07-29 国立大学法人鳥取大学 認知症治療薬または予防薬

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2073981C (en) * 1990-11-30 2002-01-08 Shiro Kondo 2-arylthiazole derivatives and pharmaceutical composition thereof
HUP9902721A2 (hu) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
WO2007018687A1 (en) * 2005-07-21 2007-02-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of hyperuricemia related health consequences
US8557831B2 (en) * 2004-07-21 2013-10-15 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
WO2007019153A2 (en) 2005-08-03 2007-02-15 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
CA2630639A1 (en) * 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
JP2007210978A (ja) * 2006-02-13 2007-08-23 Hiroshima Univ 耐糖能障害、ｉｉ型糖尿病、高脂血症、メタボリックシンドローム、内臓脂肪型肥満、脂肪肝または非アルコール性脂肪性肝炎の予防・治療剤
CA2669935A1 (en) 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America, Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
BRPI0819847B1 (pt) * 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
PT2266989E (pt) * 2008-03-31 2015-11-23 C&C Res Lab Derivados heterocíclicos
MX2010011603A (es) * 2008-04-30 2011-01-25 Wellstat Therapeutics Corp Compuestos de tetrazol para reducir el acido urico.
EP2291189B1 (en) * 2008-05-22 2014-10-01 AstraZeneca AB Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
WO2010045636A1 (en) * 2008-10-19 2010-04-22 Johnson Richard J Therapeutic compositions and methods for treating chronic kidney disease associated with a metabolic imbalance
WO2011022757A1 (en) * 2009-08-24 2011-03-03 Queensland University Of Technology Purine-targeted diagnosis and therapy of wounds
EP2582812B1 (en) * 2010-06-16 2018-01-24 Takeda Pharmaceuticals U.S.A., Inc. Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
AR082022A1 (es) * 2010-06-25 2012-11-07 Teijin Pharma Ltd Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal

Also Published As

Publication number Publication date
IN2014DN05972A (enExample) 2015-06-26
EP2808018A4 (en) 2015-07-15
EP2808018B1 (en) 2018-03-14
RU2014134845A (ru) 2016-03-20
US20150005506A1 (en) 2015-01-01
AU2013212865A1 (en) 2014-08-14
WO2013111870A1 (ja) 2013-08-01
CN104066430A (zh) 2014-09-24
JP5924699B2 (ja) 2016-05-25
JPWO2013111870A1 (ja) 2015-05-11
EP2808018A1 (en) 2014-12-03
TW201334779A (zh) 2013-09-01
CA2862602A1 (en) 2013-08-01
MX2014008484A (es) 2014-10-14
BR112014017902A2 (pt) 2017-08-22
KR20140134266A (ko) 2014-11-21
AR089812A1 (es) 2014-09-17

Similar Documents

Publication Publication Date Title
JP5924699B2 (ja) 糖尿病の治療薬
TWI621624B (zh) 合成的三萜系化合物及其使用於治療疾病之方法
RU2627591C2 (ru) Терапевтический или профилактический агент для синдрома распада опухоли
KR101477480B1 (ko) 스테로이드 요법에 있어서의 부작용의 개선·억제용 조성물
JP4569106B2 (ja) 臓器線維化抑制剤
JPH05506430A (ja) インスリン感性化剤類の高血圧治療のための使用
EP4122495A1 (en) Treatment or prevention method for chronic heart failure
KR101333876B1 (ko) 당·지질 대사 이상의 예방 및/또는 치료약
JP2019521160A (ja) Ｃ反応性タンパク質関連疾患の治療のための１−メチルニコチンアミド
US20040171627A1 (en) Treatment of renal fibrosis
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
US9241952B2 (en) Method of treating type II diabetes, hyperglycemia or hypoglycemia by administering a synergistic combination of a sulphonylurea and inulin
KR20130075442A (ko) 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물
WO2006064826A1 (ja) FBPase阻害剤を含有する医薬組成物
JP2020143037A (ja) 糖尿病合併心不全の治療用医薬組成物
WO2023014748A1 (en) Nitrated fatty acids for the treatment of sickle cell disorders
EP3804756A1 (en) Metabolism improving agent
WO2016133069A1 (ja) 心不全の予防又は治療のための医薬
JP5360933B2 (ja) ニトロソニフェジピン誘導体を有効成分とする糖尿病性腎症治療剤
WO2010098475A1 (ja) 摂食障害予防及び治療剤
Agent Pr SUTENT®
HK40077878A (en) Treatment or prevention method for chronic heart failure
EP1752157A1 (en) Prevention and treatment of atherosclerosis with lithospermate B
Cranston et al. Management-Complications and Comorbidities
JP2007091641A (ja) ２型糖尿病治療用の併用医薬